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Abstract 
Background:  
The amount of insulin needed to effectively treat T2DM effectively worldwide is 
unknown. It also remains unclear how alternative treatment algorithms would affect 
insulin use and T2DM complication rates, given insulin access. 
 
Methods: 
We developed a microsimulation of T2DM burden from 2018 to 2030 across 221 
countries using data from the International Diabetes Federation (IDF) for prevalence 
projections and from fourteen cohort studies representing >60% of the global T2DM 
population for haemoglobin A1c (A1c), treatment, and weight data. We estimated the 
number of people with T2DM expected to use insulin, international units (IU) required, 
and disability adjusted life years (DALYs) gained per year under alternative treatment 
algorithms targeting A1c from 6.5% to 8%, lower microvascular risk, or higher A1c for 
those >75 years old.  
 
Results: 
The number of people with T2DM worldwide was estimated to increase from 405.6 
million in 2018 to 510.8 million in 2030. Insulin use would increase from 516.1 million 
1000IU vials (95% CI: 409.0, 658.6 million) to 633.7 million per year (95% CI: 500.5, 
806.7 million) from 2018 to 2030. Without improved insulin access, 7.4% (95% CI: 
5.8%, 9.4%) of people with T2DM in 2030 would use insulin, increasing to 15.5% (95% 
CI: 12.0% to 20.3%) if insulin were widely accessible and prescribed to achieve a 
A1c<7% (53 mmol/mol). If A1c<7% was universally achieved, insulin would avert 
331,000 DALYs per year by 2030 (95% CI: 256,600, 437,100). DALYs averted would 
increase 14.9% with access to newer oral glycemic agents. DALYS averted would 
increase by 44.2% if targeting A1c of 8% (64 mmol/mol) among people >75 years old, 
due to less hypoglycaemia.  
 
Discussion: 
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The insulin required to treat T2DM is expected to increase by over 20% from 2018 to 
2030, and may avert more DALYs if A1c targets are higher for older adults. 
 
Funding: The Leona M. and Harry B. Helmsley Charitable Trust 
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Introduction 
The prevalence of diabetes worldwide has nearly quadrupled since 1980.1 Adult 
diabetes prevalence (both type 1 and type 2) reached 425 million people in 2017 (~ 1 in 
11 adults).2 Around 12% of overall global healthcare expenditures are spent on diabetes 
treatment.2 
Insulin is necessary for all people with type 1 diabetes mellitus (T1DM) and a 
subset of patients with T2DM to avoid morbidity and mortality from ketoacidosis or 
hyperosmolar hyperglycaemic states, and to reduce long-term microvascular 
complications. The use of insulin for T2DM is dependent on treatment algorithms, 
particularly the target level of haemoglobin A1c (A1c).3 Finding an optimal target that 
maximizes disability-adjusted life years (DALYs) gained, while minimizing disutility 
from insulin therapy (e.g., from hypoglycaemia) remains an important goal.4 Insulin 
treatment is relatively costly,5 with most insulin produced by three major manufacturers.2 
Hence, a prospective estimation of global insulin requirements and the DALYs averted 
by improving access may help plan what resources are required to deliver insulin. 
Complicating such estimations are the increasing numbers of people with T2DM, 
increasing survival of people with T2DM (which may increase insulin requirements), and 
increasing availability of newer oral diabetes treatments. 
Here, we sought to estimate global insulin utilization for T2DM by country and 
year, worldwide, from 2018 to 2030 and the potential impacts of altering insulin 
treatment algorithms on insulin use and diabetes-related burden of disease.  
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Methods 
 
 A microsimulation (Figure 1) was constructed to simulate the population of 
adults with T2DM within each of 221 countries and territories worldwide to estimate the 
number of adults utilizing insulin, and to estimate the international units (IU) of insulin 
used under alternative treatment algorithms. IDF estimates for T2DM prevalence were 
multiplied by IDF estimates of the proportion of people diagnosed and then by the 
number estimated to need insulin (Appendix Table 1). The proportion estimated to need 
insulin was calculated in two ways, detailed below: (i) an approach using current 
estimates of insulin treatment from cohort studies; and (ii) an approach based on 
theoretical comprehensive insulin access (Table 1). In both cases, we used weight-based 
dosing and varied the A1c treatment target, then used the RECODe equations6,7 to 
estimate the DALYs averted from microvascular complications by insulin treatment, and 
a new risk equation to estimate the DALYs caused by hypoglycaemia events requiring 
medical attention (Appendix Table 2).  
 
Type 2 diabetes prevalence estimation 
Diabetes prevalence (both diagnosed and undiagnosed)  among adults in each 
country and year in the simulation was taken from projections made by the International 
Diabetes Federation (IDF) for the period 2018-2030.2 The IDF prevalence estimates were 
based on a regression model using data from a systematic review of literature for the 
individual country or nearest neighbourhood; the reviewed data were used by the IDF to 
generate smoothed sex- and age-specific prevalence estimates for adults 20–79 years old, 
which were projected by the IDF into the future using UN population projections and 
assuming that the age- and sex-specific prevalence of diabetes would increase linearly 
with urbanization.8 This conservative assumption produces a lower-bound estimate of 
future diabetes prevalence. Confidence intervals were constructed by the IDF by 
bootstrapping across study prevalence estimates in the systematic review, for which one 
study was removed from the data pool at a time. The prevalence estimates were for 
overall diabetes; based on a recent systematic review and projections, we estimated that 
96.5% of total diabetes among adults could be attributed to T2DM9 (varied in uncertainty 
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analyses to the range 92% to 99%). The estimate was based on a modelling exercise with 
extrapolation of ratios of incidence of T1DM in children to adults from available data 
applied to country-specific childhood T1DM incidence estimates.9 
 
Insulin needs estimate 
We undertook two parallel approaches to estimating the number of people 
utilizing insulin within each simulated country: (i) an approach accounting for 
demographic change but unchanged insulin access, which applied estimated proportions 
of people with T2DM currently treated with insulin to the estimated numbers of people 
with diagnosed T2DM in the future, and (ii) an approach accounting for demographic 
change and comprehensive insulin access, which estimated how many more people 
would be treated if all those estimated to need treatment with insulin under different 
treatment scenarios were provided with insulin, following appropriate oral glycaemic 
therapy, and conditional on a given treatment target for glycaemic control. 
In the approach accounting for demographic change alone (with unchanged 
insulin treatment rates; Figure 1A), we multiplied the absolute number of people 
projected to have diagnosed T2DM in each year over the period 2018-2030 by the 
proportion of those people who are anticipated to be treated with insulin given current 
estimates of the proportion of people with T2DM who receive insulin treatment in each 
country.2,10 The number of units of insulin required among those treated with insulin 
followed current guidelines based on weight, using the distribution of body weight 
among those diagnosed with T2DM and treated with insulin from regional surveys 
(Table 1). The estimates of body weight-based dosing assumed that 75% of those treated 
with insulin require only basal insulin at a dosage of 0.4 IU/kg/day, while the remaining 
individuals would require multiple dose injection therapy totalling 0.6 IU/kg/day.11,12 In a 
sensitivity analysis, we tested alternative assumptions, using 70% and 80% for 
proportions of people treated with insulin who require only basal insulin. 
In the approach accounting for both demographic change and improved insulin 
access (Figure 1B), we estimated the additional insulin required for the population not 
currently having access. First, we estimated the proportion of people with T2DM not 
currently receiving insulin from the geographically-closest regional diabetes survey for 
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each simulated country population, concatenating multiple surveys by taking an average 
if more than one was available (after accounting for survey sample weights from each) 
for a given country and bootstrapping across all available estimates when a close regional 
survey was unavailable. Details of each survey are provided in the Table 1, with 
comprehensive citations in the Appendix. Missing data—specifically, missing A1c 
values, body weight values, and indicators of whether or not a person was treated with 
insulin—were imputed with chained equations assuming data were missing at random,13 
followed by repeated Monte Carlo sampling from uncertainty distributions from each 
input parameter performed to estimate uncertainty.  
Among those not yet on insulin, we estimated whether or not insulin would be 
necessary after maximum treatment with oral glycaemic agents to achieve a given target 
A1c level (detailed below). Following current World Health Organization (WHO) 
guidelines and the WHO Essential Medicines List,14,15 titration was simulated up from 
500 mg daily of metformin to 1000 mg twice daily of metformin, then if needed, further 
addition of 80 mg daily of gliclazide (a sulfonylurea), which could be titrated up to 160 
mg twice daily. We Monte Carlo sampled from the distributions of typical A1c 
reductions for the full dose of each drug (uniform distributions) from a prior meta-
analysis,16 with proportionate linear values for doses below the maximum, taking into 
account existing dosage levels among those already on oral agents. Those people still 
above the target A1c after maximum titration of oral agents were assumed to achieve the 
target A1c only by starting insulin (after discontinuing the sulfonylurea) and setting their 
insulin use based on their weight (sampling from the weight estimates from the closest 
regional survey), estimating that 75% of those treated with insulin require only basal 
insulin at a dosage of 0.4 IU/kg/day (varied from 70% to 80% in sensitivity analyses), 
while the remaining individuals would require multiple dose injection therapy totalling 
0.6 IU/kg/day.11,12Among the population already receiving insulin, we estimated total 
daily insulin needed using these same estimates of total units per kilogram required per 
day. 
Finally, we conducted a sensitivity analysis to estimate how much less insulin 
may be required if newer agents were more widely available (e.g., GLP-1 agonists, DPP-
4 inhibitors, and SGLT-2 inhibitors) and combined with metformin instead of combining 
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a sulfonylurea with metformin; we used the A1c reductions estimated in a recent meta-
analysis to estimate the A1c effects of these newer agents.17 
 
Treatment targets 
 For the scenario accounting for both demographic change and improved insulin 
access, we simulated five different treatment targets. Recognizing that some 
facilities lack A1c testing, we converted to the nearest average fasting plasma 
glucose (AFPG) target level.16 We used the 2018 American Diabetes Association 
treatment guidelines as a primary clinical reference.18 
 First, we set the target A1c to 7.0% (53 mmol/mol) for all diagnosed and treated 
persons (AFPG = 8.0 mmol/L). 
 Second, we reduced the target A1c to a low of 6.5% (48 mmol/mol; AFPG = 7.5 
mmol/L). 
Third, we increased the target A1c to a high of 8.0% (64 mmol/mol; AFPG = 9.2 
mmol/L). 
 Fourth, we simulated an age-based target, with persons <75 years old given an 
A1c target of 7% and those >75 years old given a target A1c of 8%.19,20 
 Fifth, we simulated a risk-based target, with persons having >5% risk over 10 
years of composite microvascular complications (renal failure/end-stage renal disease, 
severe vision loss <20/200 on a Snellen chart, or loss of pressure sensation by 
monofilament testing) estimated from the RECODe equations6,7 treated with insulin to an 
A1c of 7% or the A1c level that achieved an estimated risk <5% (whichever A1c was 
higher). The threshold was based on prior experiments for risk-based therapy.21 
 
Outcome 
 The primary outcome metric we estimated was the number of people with T2DM 
estimated to use insulin for each year in each country and each world region (using 
United Nations categorizations of countries into regions). 
The secondary outcome metric was the number of 10mL vials of U100 insulin 
(i.e., 1,000IU) used per year in the total population of each country and each world region 
for each year from 2018 to 2030. 
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 For the scenario accounting for both demographic change and improved insulin 
access, the additional outcome metric was the DALYs averted by achieving the insulin 
treatment levels simulated. We computed the DALYs averted from each of three 
microvascular complications (renal failure/end-stage renal disease, severe vision loss 
<20/200 on a Snellen chart, or loss of pressure sensation by monofilament testing) using 
the RECODe equations for baseline risk for each complication re-calibrated to global 
DALY estimates from the Global Burden of Disease Project,6,7,22 the relative risk 
reduction conditional on A1c reduction for each complication from a prior systematic 
review,23 and the disability weights provided by a prior international survey (Appendix 
Table 3).24 We also computed the increase in DALYs due to: (i) the disutility of daily 
finger stick glucose monitoring; (ii) disutility from injection therapy, and (iii) disutility 
due to hypoglycaemia requiring hospitalization, emergency care, or other external 
medical assistance due to severe cognitive impairment, based on a risk equation to 
estimate the frequency of hypoglycaemia (Appendix Table 3). The hypoglycaemia risk 
equation was based on individual participant data from the ACCORD trial, and was a 
multivariable equation incorporating demographics, insulin units used, and related 
treatment covariates (Appendix Table 2). DALYs were computed at a standard 3% 
annual discount rate, integrated over the full life-course of all simulated individuals. 
 Outcomes were computed up to the year 2030, and additionally for the midpoint 
year of analysis (2024) for comparison. 
All estimates were performed in R (v. 3.4, R Foundation for Statistical 
Computing, Vienna), using the code deposited at 
https://github.com/sanjaybasu/insulinestimates for reproducibility.  
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Results 
 First, we simulated the approach accounting for demographic change alone (with 
unchanged insulin access. The number of people projected to have T2DM over the period 
2018-2030 based on IDF estimates2 were 405.6 million in 2018 (95% CI: 315.3, 533.7 
million) and 510.8 million in 2030 (95% CI: 395.9, 674.3 million). The estimated number 
of people with T2DM in each country was typically proportional to population size, with 
the largest absolute number in 2018 residing in China (111.9 million; 95% CI: 97.1, 
146.3 million; 7.9% prevalence) and India (72.5 million; 95% CI: 52.8, 91.9 million; 
5.4% prevalence), followed by the United States, which had a higher prevalence (29.3 
million; 95% CI: 26.7, 31.7 million; 9.0% prevalence). Projections for the year 2030 by 
the IDF2 were proportional to anticipated population growth, aging, and urbanization in 
less developed countries, with the largest absolute numbers of people with T2DM 
projected to be in China (130.2 million; 95% CI: 113.4, 163.3 million; 9.0% prevalence), 
India (98.0 million; 95% CI: 73.7, 122.9 million; 6.5% prevalence), then the United 
States (31.8 million; 95% CI: 28.7, 34.5 million; 9.0% prevalence). When we combined 
data on the number of people with T2DM with the proportions diagnosed and treated 
with insulin,2,10 we estimated that insulin utilization would increase from 516.1 million 
1000-unit vials (95% CI: 409.0, 658.6 million) to 633.7 million vials per year (95% CI: 
500.5, 806.7 million) between 2018 and 2030. The number of vials utilized decreased or 
increased by 2% if the proportion of people treated with basal insulin only decreased 
from 75% to 70% or increased to 80%. The absolute number of people estimated to use 
insulin and the number of U100 insulin vials required would be lowest in the Oceanic 
region (4.2 million vials in 2030) and highest in Asia (321.6 million vials in 2030) due to 
population size (Table 2). In relative terms, the proportion of people with diagnosed 
T2DM utilizing insulin would be lowest in the African region due to low medication 
access and low prevalence of T2DM (1.8% of people with T2DM treated with insulin in 
2030) and highest in the Americas region in the context of greater insulin use and higher 
T2DM prevalence (13.6% of people with T2DM treated with insulin in 2030). 
 Second, we simulated both demographic change and improved insulin access. We 
estimated the proportion of people diagnosed with T2DM who could receive insulin after 
maximum oral therapy, if insulin were widely available and if providers aimed to achieve 
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a target A1c of 7% (Appendix Figure 1). The distribution of A1c among those with 
diagnosed T2DM (Table 1) had a global mean of 9.1% and 95% centiles extending from 
5.1% to 15.1%. The proportion of people with T2DM who we anticipated to use insulin 
increased from 7.4% (95% CI: 5.8%, 9.4%) to 15.5% (95% CI: 12.0% to 20.3%), on 
average, when changing from the scenario assuming persistence of current insulin access 
levels, to the scenario assuming comprehensive insulin access (Table 2). The greatest 
relative increase in number of people anticipated to use insulin between the two scenarios 
would be in the African region (7.1-fold increase from 718,800 if insulin access were at 
current levels to 5,119,900 under universal access), while the greatest absolute increase 
would be in the Asian region (+26.5 million people utilizing insulin from 21.1 million if 
insulin access were at current levels to 47.6 million under universal access). The ratio of 
actual utilization (given current insulin access levels) to estimated utilization (given 
comprehensive insulin access) varied from 0.14 in Africa to 0.71 in the Americas and 
was 0.48 worldwide. 
 We next estimated the net number of DALYs averted as a composite measure, 
accounting for the DALYs averted with comprehensive insulin access by preventing 
microvascular complications and subtracting the DALYs caused by insulin-related 
hypoglycemia and treatment-related inconvenience. When aiming for a treatment target 
of A1c of 7%, we estimated that comprehensive access to insulin would avert 263,000 
DALYs in the year 2018, increasing to 331,000 in the year 2030, with 65% of the 
DALYs averted in Asia alone (Table 2). On average, individuals reduced their composite 
lifetime risk of microvascular complications (renal failure, severe vision loss, and 
pressure sensation loss) from 17.4% to 15.9%, but increased their average lifetime risk of 
hypoglycaemia requiring medical attention from 11.9% to 20.0%. Nevertheless, due to 
the greater disutility of microvascular complications than of hypoglycaemia, overall net 
DALYs were averted through insulin treatment over the life-course, after accounting for 
the delayed onset of microvascular disease and a 3% annual discount rate on disutility 
over time. 
 Changing the target A1c produced a proportional change in the number of people 
estimated to use insulin, and in the absolute amount of insulin estimated to be required, 
though with overlapping confidence intervals based on Monte Carlo sampling (Figure 2). 
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A strict glycaemic control target of A1c = 6.5% increased the global number of people 
required to be on insulin, and the amount of insulin required, by 38.9% as compared to 
targeting A1c = 7%; conversely, a more liberal target of A1c = 8% reduced the global 
number of people required to be on insulin, and the amount of insulin required, by 45.0%. 
The overall net DALYs averted was related in a complex way to treatment targets 
(Figure 2C). In particular, targets of A1c = 6.5% or 7% had lower numbers of net 
DALYs averted than a target of 8%, as the lower levels of targeting increased DALYs 
caused by hypoglycaemia (see Figure 2D). The highest net DALYs averted was when 
targeting A1c = 7% for people <75 years old and 8% for people >75 years old, because 
this target helped avoid hypoglycaemic events that were concentrated primarily among 
older adults (Figure 2C). This age-stratified cut-off had 44.2% higher net DALYs 
averted than the universal target of 7%. Additional analyses in which the target A1c was 
risk-based (target of <5% for composite microvascular risk) was similar to the target A1c 
= 8% scenario (Figure 2C). Net DALYS averted for the midpoint year of 2024 were 
lower (by ~10%) than for the final year 2030, because of lower rates of diagnosis and 
lower total numbers of people with T2DM in 2024 than in 2030 (Appendix Figure 2). 
Finally, we conducted sensitivity analyses to estimate how much less insulin may 
be used if three types of newer agents were more widely available (GLP-1 agonists, DPP-
4 inhibitors, and SGLT-2 inhibitors) and combined with metformin instead of combining 
a sulfonylurea with metformin. The absolute number of people requiring insulin, and the 
units of insulin, did not change meaningfully given the non-significant difference from 
sulfonylurea in A1c reduction.17 However, the rate of hypoglycaemia was reduced due to 
avoidance of sulfonylurea treatment, and this increased the absolute net DALYs averted 
by 14.9%. The relative amount of net DALYs averted through each treatment target were 
not affected.  
Page 13 of 52 
Discussion 
We estimated global insulin utilization for T2DM by country and year, 
worldwide, from 2018 to 2030. We observed several major findings in the course of our 
estimation. First, we observed that current levels of insulin access are not only inadequate 
relative to projected need, but are disproportionately inadequate in the African, Asian, 
and Oceanic regions. The regions projected to increase insulin utilization most if access 
were improved were the African region in relative terms, and the Asian region in absolute 
terms. The finding that Africa has the largest relative unmet insulin need also highlights 
the importance of availability and affordability improvements to the insulin market. Asia 
would similarly be expected to use the most insulin whether or not insulin access 
improved. Second, we observed that the DALYs averted through insulin therapy would 
be highest if targeting A1c levels of 7% for younger adults (<75 years old) and 8% for 
those of older age, to balance the risk of hypoglycaemia against the benefit of longer-
term reduced microvascular disease (though with overlapping confidence intervals 
between the alternative approaches simulated). The incremental reduction in 
microvascular risk by further lowering the A1c target was not outweighed by the increase 
in serious hypoglycaemia risk. We found that—for the overall population as a whole—
using more liberal target A1c of 8% used half as much insulin with only a 20% decline in 
DALYs saved. In comparison, intensive treatment to a goal A1c of 6.5% dramatically 
increased insulin use while increasing diabetes-related harms. Finally, we found that such 
insulin needs would be unlikely to be affected by expanded access to newer oral diabetes 
drugs, as such medicines are generally not more potent than existing drugs in reducing 
A1c;17 however, such drugs may substantially lower the risk of hypoglycaemia and 
thereby improve DALYs averted through therapy, though their cost may preclude their 
use in many situations.  
Several key assumptions should be noted. First, the projections of T2DM 
prevalence from the IDF are based on population projections and the existing 
relationships between age, sex, urbanization and diabetes prevalence. As dietary and 
physical activity environments can change in both obesogenic and disease-reducing 
ways, the IDF projections may be either optimistic or pessimistic in unpredictable 
directions. Second, the RECODE equations we used were previously derived and 
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validated from U.S. samples, though we recalibrated the baseline hazard rates of events 
here to match Global Burden of Disease estimates.6,7,22 The use of these equations 
assumes that the relationship between underlying demographics (age, sex), biomarkers 
(blood pressure, A1c) and complications is consistent across countries, which may 
neglect some ethnic variations. Third, our estimates of hypoglycaemia risk are based on a 
logistic regression (incorporating risk factors such as age and insulin dosage) internally 
cross-validated in the ACCORD study sample, but not externally validated in another 
study sample. Fourth, we used the distributions of body weight, A1c and insulin 
utilization from available cohort studies in the absence of comprehensive longitudinal 
data of high quality across all countries. Additionally, we lacked sufficient data to 
estimate the degree to which different oral antidiabetic agents have different durability in 
maintaining A1c reductions over time.25–27  
 Future research into the issues raised here should consider how key barriers to 
availability and accessibility of diagnosis and therapy in the African region in particular 
may be overcome,28 and how Ministries of Health can best prepare for the anticipated 
large increase in insulin utilization needs in the coming years.  
 Prior to such research, our study reveals that insulin utilization is likely to rise 
particularly in Asia, and that targeting a moderate threshold for control—potentially 
based in part on age as a proxy for life expectancy and co-morbidities—may help balance 
the risks of insulin therapy with longer-term microvascular benefit. 
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Putting research in context 
Evidence before this study 
We conducted a PubMed search for articles with the keywords “insulin 
utilization” and “type 2 diabetes” from 2008 through August 2018. We found seven prior 
papers on the topic. Three papers reviewed the insulin dosing needs and effectiveness of 
insulin for people with T2DM when using basal insulin with or without other antidiabetic 
medications. Two articles examined the budgetary and cost impact of basal insulin 
utilization in the United States population. The remaining two papers estimated the low 
rates of access to insulin and challenges to access in East and South Asia.  
 
Added value of this study 
By comparison to the existing literature, our current study offers a direct estimate 
of the anticipated global use of insulin among persons with T2DM, using data from large 
representative cohort studies, and directly compares the implications of alternative 
treatment targets for reducing the burden of T2DM complications.   
 
Implications of all the available evidence 
 The overall evidence suggests that the number of people requiring insulin and the 
amount of insulin required to treat T2DM is expected to increase and require substantial 
improvements to access in low- and middle-income countries. 
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Tables and Figures 
 
Table 1: Input cohort data for estimating reduction in haemoglobin A1c necessary to 
achieve treatment targets, and baseline proportion of people with T2DM treated with 
insulin, among those diagnosed with T2DM. References for each cohort dataset are 
provided in the Appendix. 
 
Dataset N with diabetes 
by prior 
diagnosis or 
labs 
Years A1c, mean 
(95% 
centiles), %  
% treated with 
insulin, among 
those diagnosed 
Weight, 
mean (95% 
centiles), kg. 
U.S. National Health and 
Nutrition Examination Survey 
1,441 2009-
2014 
7.4 (5.2, 
12.2) 
22.2 89.5 (53.7, 
148.2) 
U.S. National Institutes of Health 
Global Health Centers of 
Excellence surveys from South 
Africa 
1,842 2012 9.1 (5.4, 
14.6) 
- 83.0 (51.0, 
125.0) 
U.S. National Institutes of Health 
Global Health Centers of 
Excellence surveys from India 
1,605 2015 8.7 (5.5, 
13.4) 
- 67.9 (43.0, 
98.2) 
South Africa National Health and 
Nutrition Examination Survey 
747 2012 7.7 (5.4, 
12.8) 
4.4 78.0 (44.0, 
116.6) 
U.K. National Health Service 
National Diabetes Audit 
16,585 2016-
2017 
7.3 (5.1, 
12.1) 
12.5 80.3 (48.1, 
133.0) 
Indian Jaipur Diabetes Registry 8,699 2014 9.0 (6.3, 
14.8) 
9.1 60.4 (30.6, 
101.2) 
Swedish National Diabetes 
Register 
17,827 2016 8.4 (6.1, 
10.1) 
11.7 75.6 (48.5, 
102.7) 
Danish Adult Diabetes Registry 11,205 2014-
2015 
7.7 (5.4, 
12.7) 
15.8 70.9 (33.9, 
123.5) 
Turkish Nationwide survey of 
Glycemic and Other Metabolic 
Parameters of Patients 
with Diabetes Mellitus 
4,672 2017 7.5 (5.3, 
12.4) 
9.6 84.7 (52.2, 
117.2) 
China Health and Nutrition 
Study 
1,422 1999-
2015 
7.8 (5.2, 
12.7) 
18.3 65.5 (45.2, 
90.0) 
DiabCare study of the 
Philippines 
770 2008 8.0 (5.6, 
13.2) 
25.0 58.5 (36.2, 
85.9) 
Japan National Health and 
Nutrition Survey 
1,434 2016 7.2 (5.0, 
11.8) 
7.0 59.5 (32.2, 
90.4) 
Korea National Health and 
Nutrition Examination Survey 
1,341 2010-
2012 
8.2 (5.7, 
13.5) 
3.0 66.0 (38.5, 
93.7) 
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Joint Asia Diabetes Evaluation 
Registry 
28,111 2007-
2012 
7.7 (5.4, 
12.7) 
21.0 76.8 (58.4, 
90.0) 
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Korea National Health and 
Nutrition Examination Survey 
1,341 2010-
2012 
8.2 (5.7, 
13.5) 
3.0 66.0 (38.5, 
93.7) 
Joint Asia Diabetes Evaluation 
Registry 
28,111 2007-
2012 
7.7 (5.4, 
12.7) 
21.0 76.8 (58.4, 
90.0) 
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Table 2:  
Outcome measures by world region, when the treatment target was set to haemoglobin 
A1c equal to 7%. T2DM: type 2 diabetes mellitus; CI: confidence interval.  
 
Metric Region Demographic change only Demographic change and 
comprehensive access to insulin  
Outcome, 2018 
(95% CI) 
Outcome, 2030 
(95% CI) 
Outcome, 2018 
(95% CI) 
Outcome, 2030 
(95% CI) 
People with T2DM 
utilizing insulin, 
No. (95% CI), % 
of people with 
T2DM 
Africa 502,647 
(288,690, 
798,943), 1.8% 
718,802 
(421,154, 
1,226,177), 1.8% 
3,580,238 
(2,056,273, 
5,690,693), 12.7% 
5,119,862 
(2,999,782, 
8,733,785), 12.5% 
Americas 9,695,648 
(7,665,389, 
11,537,007), 
13.7% 
12,235,005 
(9,630,417, 
14,632,677), 
13.6% 
13,687,550 
(10,821,390, 
16,287,035), 
19.3% 
17,272,413 
(13,595,462, 
20,657,257), 19.2% 
Asia 16,684,889 
(13,361,708, 
21,796,053), 
6.4% 
21,093,158 
(16,923,703, 
27,319,674), 
6.4% 
37,619,272 
(30,126,523, 
49,143,366), 
14.4% 
47,558,556 
(38,157,723, 
61,597,425), 14.3% 
Europe 3,162,812 
(2,385,353, 
4,469,907), 7.5% 
3,372,393 
(2,469,168, 
4,761,120), 7.5% 
7,993,805 
(6,028,827, 
11,297,404), 
19.0% 
8,523,506 
(6,240,663, 
12,033,426), 18.9% 
Oceania 183,439 
(123,104, 
240,038), 7.8% 
218,324 
(155,957, 
282,674), 7.7% 
435,532 (292,280, 
569,911), 18.5% 
518,356 (370,282, 
671,140), 18.3% 
Global 
Total 
30,229,435 
(23,824,244, 
38,841,948), 
7.5% 
37,637,682 
(29,600,399, 
48,222,322), 
7.4% 
63,316,397 
(49,325,293, 
82,988,409), 
15.6% 
78,992,693 
(61,363,912, 
103,693,033), 
15.5% 
U100 insulin vials 
(1000 units each) 
used per year, 
No. (95% CI)  
Africa 8,624,782 
(4,912,881, 
13,373,521) 
12,305,853 
(7,090,162, 
20,337,229) 
61,432,374 
(34,993,342, 
95,256,567) 
87,651,814 
(50,501,623, 
144,857,489) 
Americas 185,734,884 
(148,644,626, 
218,458,562) 
229,389,030 
(182,349,618, 
271,640,903) 
262,205,836 
(209,844,740, 
308,402,539) 
323,833,311 
(257,426,785, 
383,481,167) 
Asia 255,959,077 
(206,143,552, 
334,166,375) 
321,604,383 
(259,506,395, 
415,709,828) 
577,108,650 
(464,790,030, 
753,441,950) 
725,118,538 
(585,106,758, 
937,297,246) 
Europe 62,218,758 
(46,900,997, 
88,025,335) 
66,228,854 
(48,525,714, 
93,594,458) 
157,253,927 
(118,539,269, 
222,478,398) 
167,389,188 
(122,645,636, 
236,554,000) 
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Oceania 3,517,167 
(2,388,704, 
4,588,735) 
4,170,065 
(2,989,682, 
5,383,238) 
8,350,661 
(5,671,400, 
10,894,840) 
9,900,809 
(7,098,276, 
12,781,196) 
Global 
Total 
516,054,668 
(408,990,760, 
658,612,528) 
633,698,185 
(500,461,571, 
806,665,656) 
1,066,351,448 
(833,838,781, 
1,390,474,294) 
1,313,893,660 
(1,022,779,078, 
1,714,971,098) 
DALYs averted by 
insulin treatment, 
No. (95% CI) 
Africa - - 18,321 (10,517, 
29,451) 
26,585 (15,532, 
45,613) 
Americas - - 46,019 (36,477, 
54,594) 
58,216 (45,933, 
69,554) 
Asia - - 169,807 (135,827, 
221,226) 
215,179 (172,646, 
277,939) 
Europe - - 27,208 (20,524, 
38,645) 
29,282 (21,192, 
41,539) 
Oceania - - 1,529 (999, 2,026) 1,839 (1,298, 
2,408) 
Global 
Total 
  262,884 (204,344, 
345,942) 
331,101 (256,601, 
437,053) 
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Figure 1: Study flow diagram. Each cell describes a key input data (with source 
parenthetically) or outcome estimate (with estimation approach parenthetically). Two 
approaches were used to estimate the outcomes: (i) an approach incorporating 
demographic change only (left side of dashed line) and (ii) an approach incorporating 
both demographic change and improved insulin access (right side of dashed line).  
Legend: T2DM: type 2 diabetes mellitus. IDF: International Diabetes Federation. 
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Figure 2: Variations in insulin treatment and DALYs averted under alternative treatment 
targets in the year 2030. All estimates are made with the approach defined in the Methods 
section that accounted for both demographic change and increased insulin access. The 
height of the bars reflects the mean, and error bars reflect 95% confidence intervals. 
Legend: Base case: target A1c of 7.0% (53 mmol/mol) for all diagnosed and treated 
persons (AFPG = 8.0 mmol/L); intensive: target A1c of 6.5% (48 mmol/mol; AFPG = 7.5 
mmol/L); liberal: target A1c of 8.0% (64 mmol/mol; AFPG = 9.2 mmol/L); age-tailored: 
with persons <75 years old target A1c of 7% and for those >75 years old target A1c of 
8%;19,20 risk-based: with persons having >5% risk over 10 years of composite 
microvascular complications (renal failure/end-stage renal disease, severe vision loss 
<20/200 on a Snellen chart, or loss of pressure sensation by monofilament testing) 
estimated from the RECODe equations6,7 target A1c of 7% or the A1c level that achieved 
an estimated risk <5% (whichever A1c was higher).21 Numerical values corresponding to 
these figures are provided in Appendix Table 4. 
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(A) People with type 2 diabetes mellitus estimated to use insulin 
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(B) Number of U100 insulin vials (1000 units each) used per year 
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(C) Net DALYs averted by insulin treatment 
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(D) Ratio of DALYS averted by prevention of microvascular events with insulin 
treatment, versus from DALYs induced by insulin treatment (including hypoglycaemia 
requiring medication attention, daily finger sticks, and injections), worldwide. 
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Appendix  
  
  
Details of input cohorts  
  
Due to space limitations, detailed citations for referenced cohorts were not possible to list 
in the main text. Here, we reference the input cohort data, which were obtained from: the 
U.S. National Health and Nutrition Examination Survey (N = 1,441 with diabetes, 2009-
2014);1 the U.S. National Institutes of Health Global Health Centres of Excellence 
surveys from South Africa (N = 1,842 with diabetes, 2012) and India (N = 1,605 with 
diabetes, 2015);2,3 the South Africa National Health and Nutrition Examination Survey 
(N = 747 with diabetes, 2012);4 the U.K. National Health Service National Diabetes 
Audit (N = 16,585 with diabetes, 2016-2017);5 the Indian Jaipur Diabetes Registry (N = 
8,699 with diabetes, 2014);6 the Swedish National Diabetes Register (N = 17,827 with 
diabetes, 2016);7 the Danish Adult Diabetes Registry (N = 11,205 with diabetes, 2014-
2015);8 the Turkish Nationwide survey of Glycemic and Other Metabolic Parameters of 
Patients with Diabetes Mellitus (TEMD study; N = 4,672 with diabetes, 2017);9 the 
China Health and Nutrition Study (N = 1,422 with diabetes, 1999-2015);10 the DiabCare 
study of the Philippines (N = 770, 2008);11 the Japan National Health and Nutrition 
Survey (N = 1434 with diabetes, 2016);12 the Korea National Health and Nutrition 
Examination Survey (N =  
1,341 with diabetes, 2010-2012);13 and the Joint Asia Diabetes Evaluation Registry (N = 
3,415 with diabetes from China, 15,196 from Hong Kong, 3,714 from India, 1,651 from 
Korea, 3,365 from Philippines, 692 from Vietnam, and 78 from Taiwan, 2007-2012).14 
See reference list at the end of this Appendix.  
  
Appendix Table 1:   
Estimates of absolute number of people aged 20-79 years old with T2DM for the years 
2018 and 2030, by country, based on IDF estimates.15 95% confidence intervals are in 
parentheses. Monte Carlo sampling from the Gaussian distributions around these 
estimates was performed to incorporate the prevalence estimates into the outcome 
metrics. Classification of countries into regions is based on the International Standards 
Organization (ISO-3166) standard.  
  
Country    Region   2018  2030  
 Afghanistan   Asia  1053371 (806706, 1519286)  1735972 (1315472, 2520914)  
 Albania   Europe  242142 (201328, 281372)  264658 (220480, 306960)  
 Algeria   Africa  1775544 (1182966, 2504770)  2443267 (1573364, 3432722)  
 Andorra   Europe  5899 (4841, 7776)  6629 (5412, 8665)  
 Angola   Africa  361802 (210879, 583250)  641394 (380636, 1059184)  
 Anguilla   Americas  1266 (980, 1558)  1523 (1148, 1842)  
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 Antigua and Barbuda   Americas  8376 (7318, 9858)  10808 (9248, 12797)  
 Argentina   Americas  1728226 (1161169, 2535758)  2115204 (1471724, 3121943)  
 Armenia   Asia  163474 (106228, 270722)  175315 (111916, 314755)  
 Aruba   Americas  10905 (8659, 13926)  11379 (8904, 14484)  
 Australia   Oceania  1109756 (820101, 1367965)  1307034 (964216, 1612486)  
 Austria   Europe  578860 (482250, 746813)  670050 (544232, 812824)  
 Azerbaijan   Asia  475406 (308887, 771191)  568494 (364164, 1011771)  
 Bahamas   Americas  37195 (31945, 44455)  45120 (37604, 54011)  
 Bahrain   Asia  165463 (144834, 187189)  236962 (207196, 267498)  
 Bangladesh   Asia  6964460 (5381702, 10066385)  10331890 (7818844, 17844294)  
 Barbados   Americas  34519 (29181, 41139)  36271 (29824, 43810)  
 Belarus   Europe  465478 (379258, 995696)  463867 (379892, 936213)  
 Belgium   Europe  489465 (414227, 658096)  563199 (478336, 751277)  
 Belize   Americas  31641 (26298, 37442)  46333 (38600, 54549)  
 Benin   Africa  41138 (27585, 152265)  60019 (41092, 220249)  
 Bermuda   Americas  6403 (5210, 7700)  6226 (5028, 7442)  
 Bhutan   Asia  40351 (34021, 48669)  58819 (50240, 69588)  
 Bolivia (Plurinational State of)   Americas  391655 (306674, 620737)  563271 (442596, 891327)  
 Bosnia and Herzegovina   Europe  355029 (296772, 410643)  366553 (307572, 423014)  
 Botswana   Africa  53703 (30174, 89870)  89837 (44728, 146150)  
 Brazil   Americas  12483620 (10907665,  
13871159)  
17932750 (15509660, 20284592)  
 British Virgin Islands   Oceania  2793 (1942, 3784)  3428 (2288, 4636)  
 Brunei Darussalam   Asia  40591 (32689, 50660)  51980 (40652, 64931)  
 
 Bulgaria   Europe  408496 (312315, 553814)  397173 (302744, 554026)  
 Burkina Faso   Africa  154901 (103508, 341589)  249268 (175916, 592128)  
 Burundi   Africa  137536 (96068, 275190)  249218 (148748, 601528)  
 Cabo Verde   Africa  6301 (4754, 16445)  9075 (7380, 25133)  
 Cambodia   Asia  247640 (226498, 278527)  368324 (336600, 417771)  
 Cameroon   Africa  685681 (545318, 861466)  1034476 (825916, 1290784)  
 Canada   Americas  2536461 (2310079, 3605333)  2828931 (2576316, 3963758)  
 Cayman Islands   Americas  5370 (4579, 6436)  6705 (5544, 8109)  
 Central African Republic   Africa  122645 (97436, 154276)  202814 (162116, 252807)  
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 Chad   Africa  245711 (195223, 308843)  469930 (374724, 586747)  
 Channel Islands   ‘oceania  6840 (5834, 9097)  7741 (6516, 10507)  
 Chile   Americas  1194562 (968696, 1509074)  1635503 (1330040, 2052791)  
 China   Asia  111912900 (97135933,  
146253900)  
130175500 (113405864, 163337009)  
 China, Hong Kong SAR   Asia  620164 (521920, 742623)  697720 (587656, 836408)  
 China, Macao SAR   Asia  44487 (37526, 53735)  57699 (48672, 69515)  
 Colombia   Americas  2680858 (1832041, 3681089)  3915764 (3138500, 4758026)  
 Comoros   Africa  31660 (20932, 48879)  49815 (33100, 76002)  
 Congo   Africa  149839 (119415, 187887)  223649 (178028, 280019)  
 Cook Islands   Oceania  1526 (1043, 2442)  2589 (1528, 3594)  
 Costa Rica   Americas  314064 (261502, 374354)  387305 (314724, 463165)  
 Côte d'Ivoire   Africa  218019 (157070, 533761)  317909 (246028, 834944)  
 Croatia   Europe  210704 (152018, 447248)  202784 (147784, 443270)  
 Cuba   Americas  881872 (773338, 977614)  1070122 (920228, 1216624)  
 Curaçao   Americas  18196 (13672, 22260)  19535 (14896, 24104)  
 Cyprus   Asia  91566 (59824, 154812)  110522 (72808, 183985)  
 Czech Republic   Europe  746650 (528602, 992980)  815324 (597468, 1074245)  
 Dem. People's Republic of  
Korea   
Asia  822711 (753318, 938325)  944538 (864208, 1093520)  
 Democratic Republic of the  
Congo   
Africa  1765753 (1405219, 2216557)  3191200 (2542584, 3990432)  
 Denmark   Europe  375927 (310962, 435461)  408950 (336704, 472635)  
 Djibouti   Africa  39192 (28425, 59629)  52555 (34900, 83642)  
 Dominica   Americas  5902 (4660, 7566)  6893 (5380, 8785)  
 Dominican Republic   Americas  516104 (313894, 722264)  678949 (428264, 925164)  
 Ecuador   Americas  574084 (355057, 902437)  1042334 (739484, 1498838)  
 Egypt   Africa  8222605 (4172479, 9637605)  11675690 (5564772, 13742440)  
 El Salvador   Americas  327472 (271114, 433611)  404822 (312620, 552416)  
 Equatorial Guinea   Africa  31884 (25602, 39560)  46601 (37180, 58212)  
 Eritrea   Africa  86550 (61018, 157127)  157878 (98492, 321711)  
 Estonia   Europe  53495 (36112, 105893)  55529 (37240, 107587)  
 
 Ethiopia   Africa  2544054 (1064246, 3978151)  3336534 (1757664, 6626130)  
 Faroe Islands   Europe  2397 (1821, 2953)  2668 (2032, 3340)  
 Fiji   Oceania  79510 (57164, 164640)  87198 (59204, 152327)  
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 Finland   Europe  357470 (237031, 445504)  358451 (245340, 447932)  
 France   Europe  3181527 (2521002, 3990908)  3418907 (2682628, 4305015)  
 French Guiana   Americas  13385 (11701, 14857)  22770 (19520, 25869)  
 French Polynesia   Oceania  44039 (35138, 52807)  46547 (36948, 56133)  
 Gabon   Africa  66183 (52579, 83306)  96563 (76992, 120703)  
 Gambia   Africa  14746 (13658, 46662)  24599 (22768, 75804)  
 Georgia   Asia  225317 (150554, 368704)  235271 (152488, 413941)  
 Germany   Europe  7190853 (5588558, 8179664)  6899742 (5678424, 7954977)  
 Ghana   Africa  501145 (141788, 847598)  511924 (292124, 1154934)  
 Greece   Europe  563015 (434274, 1279596)  622950 (483484, 1319760)  
 Greenland   Americas  849 (718, 2386)  849 (718, 2386)  
 Grenada   Americas  6435 (4836, 8815)  8505 (6564, 11243)  
 Guadeloupe   Americas  52018 (40238, 63217)  56121 (43180, 68749)  
 Guam   Oceania  25422 (20412, 31784)  28715 (21924, 36479)  
 Guatemala   Americas  763886 (473673, 1164502)  1214721 (719884, 1832447)  
 Guinea   Africa  123083 (85569, 282608)  185116 (134140, 450028)  
 Guinea Bissau   Africa  18484 (13696, 46298)  26982 (20728, 69537)  
 Guyana   Americas  51156 (41715, 70268)  58466 (46160, 78326)  
 Haiti   Americas  350988 (222919, 621926)  493518 (319668, 1233958)  
 Honduras   Americas  293829 (198434, 489075)  510330 (369760, 745513)  
 Hungary   Europe  681856 (496396, 1228223)  679389 (486028, 1212655)  
 Iceland   Europe  17607 (11734, 22278)  20689 (14316, 26110)  
 India   Asia  72515680 (52780422,  
91884372)  
97984690 (73723892, 122943283)  
 Indonesia   Asia  10163610 (8389611,  
11282555)  
13129440 (10981832, 14695560)  
 Iran (Islamic Republic of)   Asia  4985973 (3696940, 6758239)  7085210 (5164852, 9596423)  
 Iraq   Asia  1434580 (971431, 1962382)  2304600 (1542348, 3093410)  
 Ireland   Europe  141008 (105672, 199628)  194527 (147192, 261218)  
 Israel   Asia  412470 (315486, 707880)  547151 (418148, 929804)  
 Italy   Europe  3306987 (2859446, 3951471)  3591734 (3115728, 4275263)  
 Jamaica   Americas  205859 (158151, 266600)  252008 (189212, 318552)  
 Japan   Asia  6950767 (5638516, 9349323)  6587593 (5347852, 8802972)  
 Jordan   Asia  410733 (322997, 703945)  613262 (490512, 1039147)  
 Kazakhstan   Asia  799934 (524211, 1306241)  923920 (595472, 1664134)  
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 Kenya   Africa  470785 (171369, 1779367)  806258 (422092, 3754071)  
 Kiribati   Oceania  12797 (6143, 17968)  15239 (9316, 20695)  
 
 Kuwait   Asia  444198 (370884, 535420)  668372 (520308, 923989)  
 Kyrgyzstan   Asia  218023 (146004, 341813)  276854 (184644, 518304)  
 Lao People's Democratic  
Republic   
Asia  117111 (107077, 131677)  188192 (171968, 212187)  
 Latvia   Europe  98313 (75696, 126425)  97482 (74904, 124426)  
 Lebanon   Asia  570006 (442046, 717728)  631496 (493992, 791828)  
 Lesotho   Africa  30410 (17370, 52206)  44457 (26764, 74220)  
 Liberia   Africa  44374 (32937, 109938)  66648 (51052, 171580)  
 Libya   Africa  437317 (311660, 584694)  560971 (375812, 733194)  
 Liechtenstein   Europe  2747 (2224, 3049)  2828 (2416, 3168)  
 Lithuania   Europe  104959 (88282, 155223)  105609 (89256, 154040)  
 Luxembourg   Europe  24284 (15688, 43049)  30251 (19024, 52832)  
 Macedonia   Europe  183613 (152635, 213221)  200313 (167184, 231811)  
 Madagascar   Africa  383087 (242477, 632602)  662649 (397056, 1074326)  
 Malawi   Africa  204442 (123182, 363926)  390955 (233836, 655957)  
 Malaysia   Asia  3466658 (2959475, 4092486)  4621662 (3981568, 5390309)  
 Maldives   Asia  18534 (15510, 43272)  27637 (21904, 46345)  
 Mali   Africa  146026 (102960, 345065)  237180 (174864, 594194)  
 Malta   Europe  41073 (22387, 51804)  43882 (23976, 54975)  
 Marshall Islands   Oceania  10164 (6578, 13797)  9621 (6252, 12805)  
 Martinique   Americas  49261 (36674, 59706)  46920 (35388, 57433)  
 Mauritania   Africa  42990 (31600, 107666)  62440 (49240, 168657)  
 Mauritius   Africa  221730 (90222, 262526)  244800 (159088, 290294)  
 Mexico   Americas  11967890 (5741522,  
14647724)  
16274520 (8313900, 19977102)  
 Micronesia (Fed. States of)   Oceania  6123 (4406, 9030)  9310 (6720, 12960)  
 Moldova   Europe  187254 (148553, 264791)  234445 (191724, 321294)  
 Monaco   Europe  2131 (1716, 2609)  2337 (1884, 2914)  
 Mongolia   Asia  96291 (30782, 176701)  119723 (40588, 221205)  
 Montenegro   Europe  56089 (46628, 65102)  59024 (49196, 68310)  
 Montserrat   Americas  459 (402, 532)  524 (484, 620)  
 Morocco   Africa  1635004 (1231678, 2652294)  2241846 (1663352, 3484550)  
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 Mozambique   Africa  300071 (192576, 541431)  511798 (303768, 935847)  
 Myanmar   Asia  1449515 (1038224, 2298843)  2643735 (1932512, 3837701)  
 Namibia   Africa  46147 (27030, 73564)  72560 (43600, 120216)  
 Nauru   Oceania  1460 (1051, 1889)  1611 (1080, 2101)  
 Nepal   Asia  657108 (435670, 1369372)  931796 (640284, 2063810)  
 Netherlands   Europe  943684 (676032, 1284715)  1037266 (736944, 1333805)  
 New Caledonia   Oceania  44820 (33930, 56061)  47902 (38908, 57450)  
 New Zealand   Oceania  316454 (232706, 402682)  338123 (259884, 420853)  
 
 Nicaragua   Americas  367569 (233135, 515416)  454314 (319444, 631990)  
 Niger   Africa  170693 (107704, 337352)  275763 (175816, 603702)  
 Nigeria   Africa  1710470 (1199146, 4040407)  2516065 (1904492, 6480549)  
 Niue   Oceania  239 (145, 316)  214 (116, 306)  
 Norway   Europe  291620 (200209, 365860)  340100 (240044, 426634)  
 Oman   Asia  369448 (249552, 462541)  544860 (375984, 675942)  
 Pakistan   Asia  7503461 (5068829, 11156193)  10995720 (7639344, 16080949)  
 Palau   Oceania  2346 (1602, 5051)  3172 (1732, 6022)  
 Panama   Americas  217090 (169298, 273477)  321697 (266440, 380268)  
 Papua New Guinea   Oceania  634321 (278875, 888434)  837167 (530976, 1160104)  
 Paraguay   Americas  299785 (259903, 338162)  446715 (380940, 510164)  
 Peru   Americas  1133160 (804665, 1719635)  1636648 (1114620, 2588600)  
 Philippines   Asia  3701124 (2817893, 4796906)  5014895 (3728880, 6581034)  
 Poland   Europe  2165593 (1523183, 6214533)  2262371 (1604812, 5844306)  
 Portugal   Europe  1031139 (725206, 1310302)  1071754 (766572, 1346624)  
 Puerto Rico   Americas  387705 (308179, 474341)  401566 (317424, 492305)  
 Qatar   Asia  260928 (229414, 296874)  390418 (342492, 441609)  
 Republic of Korea   Asia  3394361 (2460310, 4369531)  3996904 (2934152, 5126737)  
 Réunion   Africa  107165 (77290, 129096)  122928 (90884, 162954)  
 Romania   Europe  1710243 (1045290, 2195755)  1559033 (919592, 2107770)  
 Russian Federation   Europe  8323771 (6150186, 11169173)  10296650 (5987504, 14328933)  
 Rwanda   Africa  213430 (123970, 354544)  420148 (252812, 791552)  
 Saint Kitts and Nevis   Americas  4931 (3415, 6945)  6084 (4212, 8557)  
 Saint Lucia   Americas  13939 (11368, 19314)  17232 (13648, 22873)  
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 Saint Vincent and the  
Grenadines   
Americas  8281 (6636, 11016)  10028 (7884, 12999)  
 Samoa   Oceania  7268 (4966, 16412)  8672 (5820, 20312)  
 San Marino   Europe  2033 (1667, 2397)  2345 (1912, 2763)  
 Sao Tome and Principe   Africa  1762 (1317, 4560)  2643 (2104, 7365)  
 Saudi Arabia   Asia  3851964 (2954474, 4427450)  5469494 (4091752, 6280745)  
 Senegal   Africa  137876 (94233, 321353)  221791 (163420, 561438)  
 Serbia   Europe  828088 (690590, 958688)  819075 (684648, 946715)  
 Seychelles   Africa  7640 (5501, 10600)  12474 (7920, 16860)  
 Sierra Leone   Africa  60130 (42418, 139974)  87706 (64244, 213367)  
 Singapore   Asia  593076 (492114, 685353)  692618 (569140, 805408)  
 Sint Maarten (Dutch part)   Americas  3495 (2974, 4192)  4326 (3560, 5200)  
 Slovakia   Europe  396253 (236205, 475762)  451771 (261424, 537988)  
 Slovenia   Europe  156974 (100130, 207361)  169676 (104076, 222991)  
 Solomon Islands   Oceania  43077 (22953, 65124)  62058 (36076, 93538)  
 
 Somalia   Africa  222422 (158073, 374171)  386390 (244276, 708242)  
 South Africa   Africa  1829207 (1014950, 3729624)  2633569 (1367424, 5259500)  
 South Sudan   Africa  433982 (310884, 579605)  645568 (456804, 857835)  
 Spain   Europe  3497947 (2621566, 5015841)  3964455 (2929116, 5663136)  
 Sri Lanka   Asia  1168936 (791970, 1819035)  1322407 (882028, 2060194)  
 State of Palestine   Asia  172415 (104868, 364354)  286916 (158268, 610090)  
 Sudan   Africa  2218476 (1089710, 3758088)  2819352 (1451136, 5413432)  
 Suriname   Americas  44747 (29465, 89601)  52974 (38484, 82308)  
 Swaziland   Africa  17008 (9794, 29913)  23890 (14388, 40543)  
 Sweden   Europe  482449 (392324, 653875)  490056 (389996, 715770)  
 Switzerland   Europe  459769 (432382, 684840)  541227 (503700, 748367)  
 Syrian Arab Republic   Asia  726032 (547335, 996339)  1266416 (962324, 1724851)  
 Taiwan   Asia  1904876 (1362021, 2516152)  2090333 (1509376, 2722720)  
 Tajikistan   Asia  266955 (179299, 410837)  372998 (251064, 691050)  
 Thailand   Asia  4106930 (2998277, 4839127)  4654619 (3261984, 5423349)  
 Timor-Leste   Asia  32923 (27522, 38308)  47021 (40612, 53809)  
 Togo   Africa  172842 (49037, 278306)  253791 (78192, 408005)  
 Tokelau   Oceania  206 (110, 273)  252 (100, 340)  
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 Tonga   Oceania  7129 (4649, 11318)  8609 (6228, 13838)  
 Trinidad and Tobago   Americas  115823 (91386, 157592)  145971 (121328, 181037)  
 Tunisia   Africa  751936 (563012, 1137407)  948897 (631676, 1366639)  
 Turkey   Asia  6625234 (5664827, 8081333)  8606189 (7377472, 10455463)  
 Turkmenistan   Asia  208272 (133923, 339282)  269369 (172880, 485995)  
 Tuvalu   Oceania  1697 (956, 2210)  1561 (836, 2354)  
 Uganda   Africa  297550 (165203, 674855)  867422 (494512, 2022548)  
 Ukraine   Europe  2729566 (1770750, 4692247)  2639892 (1687936, 4777706)  
 United Arab Emirates   Asia  1186784 (1005931, 1415700)  1699868 (1429464, 2034054)  
 United Kingdom   Europe  2682726 (2288142, 3600088)  3056956 (2574424, 4210151)  
 United Republic of Tanzania   Africa  939479 (578124, 2090382)  1826426 (1129524, 3882806)  
 United States of America   Americas  29338180 (26690902,  
31679401)  
31825320 (28715312, 34490266)  
 United States Virgin Islands   Oceania  11811 (9450, 14098)  11106 (8912, 13266)  
 Uruguay   Americas  149073 (118525, 196662)  168875 (125384, 261274)  
 Uzbekistan   Asia  1220580 (680900, 2050170)  1550373 (919460, 2841012)  
 Vanuatu   Oceania  16776 (12277, 25124)  30838 (22040, 42794)  
 Venezuela (Bolivarian Republic 
of)   
Americas  1369611 (1021586, 1905704)  2618469 (2032188, 3329925)  
 Viet Nam   Asia  3520101 (2736766, 4858207)  4818023 (3490424, 7353720)  
 Western Sahara   Africa  9552 (8184, 25873)  12658 (10896, 36979)  
 Yemen   Asia  543920 (401731, 1001477)  927772 (694008, 1597533)  
 Zambia   Africa  230349 (132762, 377875)  423312 (252392, 703175)  
 Zimbabwe   Africa  114253 (70434, 467417)  334696 (202784, 668168)  
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 Appendix Table 2:   
  
(A) RECODe equations used to estimate rates of microvascular complications of 
T2DM. The 10-year risk of an outcome can be computed as 1- lambda^exp(sum(beta*x) 
– mean(sum(beta*x))), where beta are the equation coefficients and x are the values for 
each covariate for an individual patient within the cohort under study. Lambda values 
were 0.973 for renal failure/ESRD, 0.921 for vision loss, and 0.870 for loss of pressure 
sensation. After the equations’ baseline hazard rates were recalibrated to match DALY 
estimates from the Global Burden of Disease project for each complication (see GBD 
website for cause-specific DALY estimates),22 the mean(sum(beta*x)) values were 1.37 
for renal failure, 130.9 for severe vision loss, and 4.99 for pressure sensation loss. To 
estimate the reduction in risk with treatment, we used estimates from a prior systematic 
review, in which the risks were first converted to rates (where initial rate = -ln(1-
risk)/10, then calculated the new reduced rate of each treatment as (initial rate * (new 
A1c/initial A1c)b), where b is 1.14 for renal failure, 1.29 for severe vision loss , and 1.19 
for pressure sensation loss.4 The new A1c was calculated from initial A1c as noted in the 
main text, by using values from a meta-analysis to estimate reduction with each 
treatment (typically 1-2% reduction with each oral medication, then reduction to target 
A1c level with insulin instead of sulfonylurea if necessary).17 Blank cells indicate that 
the particular covariate is not included in the given equation (a beta coefficient of zero).  
  
Covariate  Renal 
failure/end- 
stage renal 
disease  
Severe 
vision 
loss  
Pressure 
sensation 
loss  
Age, years   –0.01938  0.02285  0.03022  
Women   –0.01129  0.2264  –0.18680  
Black   0.08812  – 
0.16770  
–0.09448  
Hispanic or  
Latino   
0.2338  -  -  
Tobacco smoking, 
current   
0.1483  -  -  
Systolic blood 
pressure, mm Hg   
0.00303  0.00824  0.00456  
 –0.02164  0.1127  0.26672  
Cardiovascular 
disease history   
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Blood pressure- 
lowering drugs   
–0.07952  0.06393  0.18192  
Oral diabetes drugs   –0.12560  – 
0.23490  
  
–0.25747  
  
Anticoagulants   0.03199    
HbA1c, %   0.1369  0.1449  0.18866  
Total cholesterol, 
mg/dL   
–0.00111  – 
0.00017  
0.00219  
HDL cholesterol, 
mg/dL   
0.00629  0.00545  –0.00539  
Serum creatinine, 
mg/dL   
0.8609  0.6947  0.60442  
Urine 
albumin:creatinine 
ratio, mg/g  
0.00036  0.0002  -  
  
  
  
(B) Hypoglycaemia risk equation. The risk equation was developed from the 
ACCORD study sample (N = 10,251),16 using elastic net regularization17 for parameter 
selection and refitting to avoid imprecise standard errors. The logistic regression 
equation estimates 5-year probability of hypoglycaemia requiring medical assistance. 
The risk equation was estimated through 5-fold crossvalidation using individual 
participant data from the ACCORD trial. The equation had a C-statistic of 0.76, and 
passed the Hosmer-Lemeshow test for calibration.18 To calculate the probability of a 
hypoglycemic event requiring medical assistance, an individual’s value for each 
covariate is multiplied by the coefficient then added to the intercept to derive a sum of 
terms, then the 5-year probability of a major hypoglycaemic event equals 1/(1+exp(-sum 
of terms)).  
  
Covariate  Coefficient  Standard  
Error  
Wald Z score  P value  
Intercept  
-8.8533  3.0621  -2.89  0.0038  
Age, years  
0.0136  0.0274  0.50  0.6190  
Female   
0.2835  0.3580  0.79  0.4284  
Starting haemoglobin A1c value, %  
0.6870  0.2184  3.15  0.0017  
Change in haemoglobin A1c with therapy, %  
0.1323  0.1593  0.83  0.4063  
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Systolic blood pressure, mmHg  
-0.0026  0.0098  -0.26  0.7924  
Alanine aminotransferase, mg/dL  
-0.0472  0.0195  -2.42  0.0157  
Loss of foot vibratory sensation   0.5126  0.4702  1.09  0.2757  
Units of insulin per day  
0.0005  0.0046  0.12  0.9080  
On sulfonylurea   
-0.3323  0.4269  -0.78  0.4363  
Severe vision loss   
0.0226  0.3919  0.06  0.9540  
Serum creatinine, mg/dL  1.1783  0.7396  1.59  0.1112  
Time since diabetes diagnosis, years  
0.0391  0.0226  1.73  0.0844  
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Appendix Table 3:   
Disability weights used for estimating DALYs averted through insulin treatment, based 
on a prior global survey and systematic review.19   
  
Disease outcome  Utility value (95% CI)  
Renal failure/end-stage renal disease  0.573 (0.397, 0.749)  
Severe vision loss  0.191 (0.129, 0.269)  
Pressure sensation loss  0.099 (0.066, 0.145)  
Hypoglycaemia requiring medical attention  0.054 (0.033, 0.084)  
Daily finger sticks and injections  0.009 (0.004, 0.018)  
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Appendix Table 4:   
Numerical values corresponding to main text Figure 2. 95% confidence intervals are 
listed in parentheses.  
  
(A) People with type 2 diabetes mellitus estimated to use insulin  
  
  
 Base case (7%)  Intensive (6.5%)  Liberal (8%)  Age-tailored (7%  
(<75yo), 8%  
(>75yo))  
Risk based (<5%  
risk)  
Africa  5119862 (2999782,  
8733785)  
7112791 (4167460,  
12133449)  
2818170 (1651196,  
4807412)  
5838439 (3420804,  
9959579)  
7112791 (4167460,  
12133449)  
Americas  17272413  
(13595462,  
20657257)  
23995776  
(18887556,  
28698186)  
9507403 (7483467,  
11370552)  
19696612  
(15503597,  
23556522)  
23995776  
(18887556,  
28698186)  
Asia  47558556  
(38157723,  
61597425)  
66070932  
(53010784,  
85574492)  
26178065  
(21003483,  
33905600)  
54233441  
(43513193,  
70242677)  
66070932  
(53010784,  
85574492)  
Europe  8523506 (6240663,  
12033426)  
11841319 (8669869,  
16717489)  
4691667 (3435102,  
6623662)  
9719788 (7116546,  
13722328)  
11841319 (8669869,  
16717489)  
Oceania  518356 (370282,  
671140)  
720129 (514416,  
932385)  
285323 (203818,  
369422)  
591108 (422252,  
765336)  
720129 (514416,  
932385)  
  
  
(B) Number of U100 insulin vials (1000 units each) used per year  
  
 Base case (7%)  Intensive (6.5%)  Liberal (8%)  Age-tailored (7%  
(<75yo), 8%  
(>75yo))  
Risk based (<5%  
risk)  
Africa  87651814  
(50501623,  
144857489)  
121770667  
(70159601,  
201243902)  
48246941  
(27798042,  
79735153)  
99953823  
(57589570,  
165188365)  
121770667  
(70159601,  
201243902)  
Americas  323833311  
(257426785,  
383481167)  
449886847  
(357631290,  
532752893)  
178250353  
(141697638,  
211082835)  
369283600  
(293556860,  
437303085)  
449886847  
(357631290,  
532752893)  
Asia  725118538  
(585106758,  
937297246)  
1007374109  
(812862130,  
1302144310)  
399133230  
(322065343,  
515924581)  
826889561  
(667227005,  
1068847737)  
1007374109  
(812862130,  
1302144310)  
Europe  167389188  
(122645636,  
236554000)  
232546164  
(170385988,  
328633682)  
92137470  
(67508892,  
130208452)  
190882407  
(139859059,  
269754561)  
232546164  
(170385988,  
328633682)  
Oceania  9900809 (7098276,  
12781196)  
13754743 (9861312,  
17756333)  
5449788 (3907165,  
7035264)  
11290397 (8094526,  
14575048)  
13754743 (9861312,  
17756333)  
  
  
(C) Net DALYs averted by insulin treatment  
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 Base case (7%)  Intensive (6.5%)  Liberal (8%)  Age-tailored (7%  
(<75yo), 8% (>75yo))  
Risk based (<5%  
risk)  
Africa  26585 (15532,  
45613)  
19091 (11154,  
32755)  
33817 (19757,  
58020)  
38336.45 (22397.44,  
65774.21)  
33471 (19555,  
57426)  
Americas  58216 (45933,  
69554)  
41806 (32985,  
49948)  
74051 (58428,  
88474)  
83947.72 (66236.61,  
100298.18)  
73293 (57830,  
87569)  
Asia  215179 (172646,  
277939)  
154524 (123981,  
199593)  
273711 (219609,  
353543)  
310291.43 (248958.82,  
400792.63)  
270909 (217360,  
349923)  
Europe  29282 (21192,  
41539)  
21028 (15218,  
29830)  
37247 (26956,  
52839)  
42224.94 (30558.64,  
59900.63)  
36865 (26680,  
52298)  
Oceania  1839 (1298, 2408)  1321 (932, 1729)  2339 (1652, 3063)  2651.63 (1872.66,  
3472.36)  
2315 (1635, 3031)  
  
  
(D) Ratio of DALYS averted by prevention of microvascular events with 
insulin treatment, versus from DALYs induced by insulin treatment 
(including hypoglycaemia requiring medication attention, daily finger 
sticks, and injections), worldwide.  
Target A1c =  
7%  
Target A1c = 6.5%  Target A1c = 8%  Target A1c = 7%  
(<75yo), =8% (>75yo)  
Target risk <5%  
2.0 (1.4, 3.4)  1.5 (1.1, 2.6)  6.0 (4.2, 10.2)  4.3 (3.0, 7.4)  6.0 (4.2, 10.2)  
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Appendix Figure 1:   
Proportion of people with T2DM who would receive insulin if targeting A1c of 7% after 
maximum oral therapy, if insulin were widely available.  
  
  
  
  
Appendix Figure 2:   
Variations in insulin treatment and DALYs averted under alternative treatment targets in 
the year 2024. All estimates are made with the approach defined in the Methods section 
that accounted for both demographic change and increased insulin access. The height of 
the bars reflects the mean, and error bars reflect 95% confidence intervals.  
  
 (A)  People with type 2 diabetes mellitus estimated to use insulin  
  
 90,000,000 
Page 47 of 52 
 80,000,000 
 
70,000,000 
 
60,000,000 
 
50,000,000 
 
40,000,000 
 
30,000,000 
 20,000,000 
 10,000,000 
 - 
Base case (7%) 
Intensive (6.5%) 
Liberal (8%) 
Age-tailored (7% (<75yo), 8% (>75yo)) 
Risk based (<5% risk) 
  
  
  
(B) Number of U100 insulin vials (1000 units each) used per year  
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(C) Net DALYs averted by insulin treatment  
  
 400,000 
Number of U100 insulin vials (1000 units each), per year 
Africa Americas Asia Europe Oceania 
Page 49 of 52 
 
(D) Ratio of DALYS averted by prevention of microvascular events with insulin 
treatment, versus from DALYs induced by insulin treatment (including 
hypoglycaemia requiring medication attention, daily finger sticks, and 
injections), worldwide.  
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